SAS Output

26-APR-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

32% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1558 295 19% 928 -629 1186 -372
ERLYTX 76 240 316% 755 679 484 408
GI 476 57 12% 179 -296 225 -251
GU 450 80 18% 251 -198 328 -122
GYN 57 0 0% 0 -57 0 -57
LEUK 150 23 15% 72 -77 52 -98
LUNG 524 100 19% 314 -209 338 -186
LYMPH 172 5 3% 15 -156 9 -163
MELAN 55 30 55% 94 39 485 430
MMYEL 147 41 28% 129 -17 91 -56
OTHER 0 14   44 44 40 40
SXQOL 0 1   3 3 1 1
Total 3665 886   2784 -874 3239 -426

26-APR-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

32% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 37 76 205% 239 202 112 75
CCD 0 527   1658 1658 1543 1543
GU 0 0   0 0 0 0
LEUK 69 5 7% 15 -53 7 -62
LUNG 43 215 500% 676 633 576 533
LYMPH 53 1 2% 3 -49 1 -52
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 0   0 0 4 4
PREV 0 16   50 50 95 95
SURV 0 37   116 116 101 101
SXQOL 878 3 0% 9 -868 6 -872
Total 1172 880   2766 1597 2445 1273

26-APR-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

32% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1595 371 23% 1167 -427 1298 -297
CCD 0 527   1658 1658 1543 1543
ERLYTX 76 240 316% 755 679 484 408
GI 476 57 12% 179 -296 225 -251
GU 450 80 18% 251 -198 328 -122
GYN 57 0 0% 0 -57 0 -57
LEUK 219 28 13% 88 -130 59 -160
LUNG 567 315 56% 991 424 914 347
LYMPH 225 6 3% 18 -206 10 -215
MELAN 55 30 55% 94 39 485 430
MMYEL 239 41 17% 129 -109 91 -148
OTHER 0 14   44 44 44 44
PREV 0 16   50 50 95 95
SURV 0 37   116 116 101 101
SXQOL 878 4 0% 12 -865 7 -871
Total 4837 1766   5552 722 5684 847

26-APR-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

32% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1012 179 18% 563 -448 604 -408
ERLYTX 76 159 209% 500 424 313 237
GI 418 36 9% 113 -304 144 -274
GU 375 58 15% 182 -192 232 -143
GYN 57 0 0% 0 -57 0 -57
LEUK 122 16 13% 50 -71 39 -83
LUNG 441 75 17% 235 -205 237 -204
LYMPH 129 4 3% 12 -116 8 -121
MELAN 55 18 33% 56 1 256 201
MMYEL 85 39 46% 122 37 89 4
OTHER 0 14   44 44 40 40
SXQOL 0 1   3 3 1 1
Total 2770 599   1880 -884 1963 -807

26-APR-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

32% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 10 73 730% 229 219 109 99
CCD 0 379   1192 1192 1137 1137
GU 0 0   0 0 0 0
LEUK 69 5 7% 15 -53 7 -62
LUNG 30 146 487% 459 429 402 372
LYMPH 53 1 2% 3 -49 1 -52
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 0   0 0 4 4
PREV 0 8   25 25 76 76
SURV 0 25   78 78 63 63
SXQOL 740 3 0% 9 -730 6 -734
Total 994 640   2010 1019 1805 811

26-APR-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

32% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1022 252 25% 792 -229 713 -309
CCD 0 379   1192 1192 1137 1137
ERLYTX 76 159 209% 500 424 313 237
GI 418 36 9% 113 -304 144 -274
GU 375 58 15% 182 -192 232 -143
GYN 57 0 0% 0 -57 0 -57
LEUK 191 21 11% 66 -124 46 -145
LUNG 471 221 47% 695 224 639 168
LYMPH 182 5 3% 15 -166 9 -173
MELAN 55 18 33% 56 1 256 201
MMYEL 177 39 22% 122 -54 89 -88
OTHER 0 14   44 44 44 44
PREV 0 8   25 25 76 76
SURV 0 25   78 78 63 63
SXQOL 740 4 1% 12 -727 7 -733
Total 3764 1239   3892 135 3768 4

26-APR-2018 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

32% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2018
Accrual
to date
Percentage
of Base
Accrual
Projected
2018
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 65 248 382% 780 715 987 922
CCD 0 527   1658 1658 1543 1543
GI 81 14 17% 44 -36 37 -44
GU 215 51 24% 160 -54 130 -85
LEUK 0 5   15 15 7 7
LUNG 53 24 45% 75 22 93 40
LYMPH 7 1 14% 3 -3 1 -6
MELAN 0 2   6 6 390 390
MMYEL 0 41   129 129 91 91
OTHER 0 0   0 0 13 13
PREV 0 16   50 50 95 95
SURV 0 37   116 116 101 101
SXQOL 878 4 0% 12 -865 7 -871
Total 1299 970   3048 1753 3495 2196

26-APR-2018 6:10

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

The REPORT Procedure

Detailed and/or summarized report

Table 1

Comm. Phase Study Stat
Center
Open
Date
Months
Open
Total
Regs
Accrual
Goal
Monthly
Accrual
Rate
Date of
Expected Closure or
Temporary Closure
BREAST II S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 SWOG 07JUL2016:00:00:00 21 244 333 13.7 Oct-2018
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1   0.0  
  III A011106 Breast, Neoadj, ALTERNATE study ALLIANCE 15FEB2014:00:00:00   56   1.0  
    A011202 Breast, Nodal XRT +/- ALND ALLIANCE     67      
    A011401 Breast, adj, Stage II/III HER2-, weight loss ALLIANCE 29AUG2016:00:00:00   133   9.2  
    A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo ALLIANCE 08DEC2016:00:00:00   35   2.7  
    B51 Breast, Regional Nodal XRT NRG     25      
    B55 Brst, Adj Olaparib for BRCA,TNBC NRG 03JUL2014:00:00:00   24   0.7  
    E2112 Brst,Adv,Exemestane+/-Entinostat ECOG-ACR 02JAN2014:00:00:00   46   1.0  
    EA1151 Brst, Tomosynthesis Mammographic Screening ECOG-ACRIN 06JUL2017:00:00:00   60   10.0  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   51   1.2  
    S1207 Brst,Adj,Endocrine+/-Everolimus SWOG 03SEP2013:00:00:00 55 1576 1900 30.5 Feb-2019
    S1222 Brst,Fulv. +/- Ever. +/- Anastr. SWOG 09MAY2014:00:00:00   37 840   Feb-2015 Temp Close
    S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) SWOG 15NOV2016:00:00:00 17 178 1000 16.5 May-2022
  OTHER A221405 Breast, ET interruption, Pregnancy Outcomes ALLIANCE 15OCT2015:00:00:00   9   0.8  
    E1Z11 Brst,Genetic Predictors of AIMSS ECOG-ACRIN 10MAY2013:00:00:00   150   1.0  
CCD III A011104 Preoperative Breast MRI ALLIANCE 21FEB2014:00:00:00   13   0.5  
    A191402C PROS, Testing Decision Aids for Minority Men Alliance 14JUL2017:00:00:00   4   0.7  
    S1415CD TrACER CSF Standing Order Intervention for FN SWOG 01SEP2016:00:00:00 19 1681 3960 113.2 Dec-2019
  OTHER S1417CD Colorectal, Cost Cohort Study SWOG 13MAY2016:00:00:00 23 232 374 18.3 Nov-2018
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 06AUG2015:00:00:00   5   0.0  
    S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 15 467 707 56.8 Aug-2018
  II-III A071102 GBM, adj TMZ +/- Veliparib ALLIANCE 19SEP2014:00:00:00   40   0.5  
    ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) COG 16MAY2014:00:00:00   7   0.5  
  OTHER EAY131 MATCH ECOG-ACR 12AUG2015:00:00:00   110   1.5  
GI II A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT ALLIANCE 01DEC2016:00:00:00   14   0.7  
    EA2142 GI NEC, Adv G3, EP vs TMZ + CAP ECOG-ACRIN 06NOV2015:00:00:00   4   0.0  
    NRGGI002 Rectal, Ph II, Sensitization using TNT NRG 12OCT2016:00:00:00   6   0.7  
    S1613 mCRC, Adv/Met, TP vs CETIRI SWOG 09OCT2017:00:00:00 6 1 130 0.2 > 15 Yrs
  II-III N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX ALLIANCE 13JAN2012:00:00:00   148   2.7  
  III A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC ALLIANCE 12SEP2017:00:00:00   2   0.3  
    NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG 07NOV2017:00:00:00   1   0.2  
    R0848 Panc, Adj, Erlotinib v ChemoRT NRG 01MAR2014:00:00:00   20   0.0  
GU II S1500 pRCC,Adv, Sunitinib vs MET inhib SWOG 05APR2016:00:00:00 24 79 180 4.5 Feb-2020
    S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab SWOG 07FEB2017:00:00:00 14 41 148 4.2 May-2020
  II-III NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG 30DEC2016:00:00:00   1   0.0  
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   3   0.2  
    EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) ECOG-ACR 02FEB2017:00:00:00   11   1.3  
    R0924 Pros, NADT+WPRT vs. NADT+P&SV RT NRG 07JUL2011:00:00:00   72   2.7  
    S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG SWOG 07FEB2017:00:00:00 14 92 969 8.2 Mar-2027
LEUK I S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP SWOG 01APR2014:00:00:00 48 38 38 0.2 Apr-2018
  I-II S1318 ALL, Age 65+, Ph±, Blinatumomab SWOG 12JAN2015:00:00:00   47 44   Sep-2017 Temp Close
  II-III S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics SWOG 22DEC2017:00:00:00 4 13 1670 3.1 > 15 Yrs
  III E1910 BCR-ABL-neg, B ALL, Blinatumomab ECOG-ACRIN 23DEC2013:00:00:00   80   2.3  
    E2906 AML, Age 60+, Clo vs Dauno+Cy ECOG-ACRIN 24FEB2011:00:00:00   75   0.0  
  OTHER NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   10   0.8  
LUNG II S1400F Non-Match: MEDI4736 + Tremelimumab SWOG 02OCT2017:00:00:00 6 17 132 2.8 Aug-2021
    S1400G HRRD: Talazoparib (BMN 673) SWOG 07FEB2017:00:00:00 14 45 60 2.5 Sep-2018
    S1400K c-Met: ABBV-399 (Process II) SWOG 05FEB2018:00:00:00 2 8 44    
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   4   0.0  
  III A081105 ALCHEMIST1, EGFR mut, Erlotinib ALLIANCE 02JAN2014:00:00:00   38   1.7  
    C30610 SCLC, Thoracic RT ALLIANCE 21MAR2008:00:00:00   55   0.5  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACR 18AUG2014:00:00:00   7   0.2  
    EA5142 ALCHEMIST3, Non-match, Nivolumab ECOG-ACRIN 16MAY2016:00:00:00   43   3.2  
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   493   17.8  
    S1400 SCCA,Adv, Biomarker Master SWOG 15JUN2014:00:00:00 46 1606   33.8  
  PILOT S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC SWOG 03NOV2017:00:00:00 5 0 28 0.0 Mar-2031
LYMPH II S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob SWOG 10AUG2017:00:00:00 8 4 150 0.7 > 15 Yrs
  III A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo ALLIANCE 15JUL2016:00:00:00   6   0.5  
    EA4151 Lymph, AHCT +/-Ritux, MRD Neg ECOG-ACRIN 29AUG2017:00:00:00   1   0.2  
MELAN II S1320 Adv, BRAF mut, Inter v Contin SWOG 22JUL2014:00:00:00 45 213 280 6.2 Feb-2019
    S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) SWOG 20OCT2016:00:00:00 18 7 77 0.7 Dec-2026
    S1607 MELAN, Adv, T-VEC, MK-3475 SWOG 02OCT2017:00:00:00 6 0 64 0.0 > 15 Yrs
    S1616 MELAN, Adv, Ipilimumab ± Nivolumab SWOG 17JUL2017:00:00:00 9 8 94 1.2 May-2024
  II-III EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   36   0.0  
  III EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T ECOG-ACR 15DEC2015:00:00:00   26   0.7  
MMYEL I-II S1211 MM,High Risk, RVD+/-ELO SWOG 27OCT2012:00:00:00   142 110   Jun-2016 Temp Close
  II S1702 AL Amyloidosis, Relapsed, Isatuximab SWOG 08MAR2018:00:00:00 1 0 39    
  III E1A11 MM, frontline, BLD vs CLD ECOG-ACRIN 22NOV2013:00:00:00   199   9.3  
OTHER I-II A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II ALLIANCE 26JAN2015:00:00:00   15   1.5  
  II A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo ALLIANCE 02SEP2014:00:00:00   2   0.0  
    A091305 HN, Adv, Thyroid PPAR agonist + Chemo ALLIANCE 01SEP2014:00:00:00   2   0.0  
    A091401 Sarc, ALLIANCE 18JUN2015:00:00:00   7   0.3  
    A091404 HN, AR+, Enzalutamide ALLIANCE 25SEP2015:00:00:00   8   0.3  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   5   0.2  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.0  
  II-III G0281 Ovar, Recur/prog LG, IC chemo vs trametinib NRG 27FEB2014:00:00:00   1   0.0  
    G0286B Adv Endometrial,Metformin/Chemo NRG     1      
    NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   3   0.0  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   4   0.2  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   3   0.0  
  III G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT NRG 12APR2010:00:00:00   1   0.0  
    N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE     6      
    NRGGY011 ENDO, SURG WINDOW, MPA VS MPA+ENTINOSTAT NRG 12APR2010:00:00:00   2   0.3  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
    R0920 HN, Adv, Postop IMRT ± Cetuximab NRG 24DEC2013:00:00:00   11   0.0  
  OTHER EAQ152 Communication & education in tumor profiling ECOG-ACR 26SEP2016:00:00:00   11   0.0  
PREV III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   3   0.0  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 61 192 480 4.7 May-2023
SURV III E1Q11 EROS: Reproductive Health in Cancer Survivors ECOG-ACR 30SEP2015:00:00:00   10   0.5  
    S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 7 6 817 1.0 > 15 Yrs
  OTHER EA9131 Leuk, Strategy to decrease early APL deaths ECOG-ACR 16AUG2017:00:00:00   8   1.0  
    S1316 Compar. Effectiv. Trial for MBO SWOG 09MAR2015:00:00:00   155 200   Apr-2018 Temp Close
SXQOL III A221101 Glioma, Nuvigil/Placebo Fatigue ALLIANCE 03JUN2013:00:00:00   20   0.5  
    NRGGU003 Pros, Post-Prostatectomy HYPORT vs COPORT NRG 28JUL2017:00:00:00   1   0.2  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

26-APR-2018 6:10

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

The REPORT Procedure

Detailed and/or summarized report

Table 1

Phase Comm. Int
grp
Stat
Center
Study NCIPROTO CA
Cntrl
Study
Temp
Close
OTHER BREAST Y ECOG-ACRIN E1Z11 Brst,Genetic Predictors of AIMSS E1Z11 Y  
    Y ALLIANCE A221405 Breast, ET interruption, Pregnancy Outcomes A221405 Y  
  CCD N   S1417CD Colorectal, Cost Cohort Study   Y  
  ERLYTX Y ECOG-ACR EAY131 MATCH EAY131 N  
  LEUK Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
  LUNG Y SWOG S1400 SCCA,Adv, Biomarker Master S1400 N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ECOG-ACR EAQ152 Communication & education in tumor profiling EAQ152 Y  
  SURV Y SWOG S1316 Compar. Effectiv. Trial for MBO S1316 Y Y
    Y ECOG-ACR EA9131 Leuk, Strategy to decrease early APL deaths EA9131 Y  
I LEUK N   S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP   N  
I-II LEUK Y SWOG S1318 ALL, Age 65+, Ph±, Blinatumomab S1318 N Y
  MMYEL Y SWOG S1211 MM,High Risk, RVD+/-ELO S1211 N Y
  OTHER Y ALLIANCE A091304 Adv Sarc, MLN0128 v Pazopanib, PhI/II A091304 N  
II BREAST Y SWOG S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 S1416 N  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI Y SWOG S1613 mCRC, Adv/Met, TP vs CETIRI S1613 N  
    Y ECOG-ACRIN EA2142 GI NEC, Adv G3, EP vs TMZ + CAP EA2142 N  
    Y NRG NRGGI002 Rectal, Ph II, Sensitization using TNT NRG-GI002 N  
    Y ALLIANCE A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT A021501 N  
  GU Y SWOG S1500 pRCC,Adv, Sunitinib vs MET inhib S1500 N  
    Y SWOG S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab S1605 N  
  LUNG Y SWOG S1400G HRRD: Talazoparib (BMN 673) S1400G N  
    Y SWOG S1400K c-Met: ABBV-399 (Process II) S1400K N  
    Y SWOG S1400F Non-Match: MEDI4736 + Tremelimumab S1400F N  
  LYMPH Y SWOG S1608 Rel/Ref FL, TGR-1202/Lenalidomide/CHOP + Ob S1608 N  
  MELAN Y SWOG S1320 Adv, BRAF mut, Inter v Contin S1320 N  
    Y SWOG S1607 MELAN, Adv, T-VEC, MK-3475 S1607 N  
    Y SWOG S1616 MELAN, Adv, Ipilimumab ± Nivolumab S1616 N  
    Y SWOG S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) S1512 N  
  MMYEL Y SWOG S1702 AL Amyloidosis, Relapsed, Isatuximab S1702 N  
  OTHER Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y ALLIANCE A091202 Sarc, Efatutazone vs Placebo, Unresect ,Lipo A091202 N  
    Y ALLIANCE A091401 Sarc, A091401 N  
    Y ALLIANCE A091305 HN, Adv, Thyroid PPAR agonist + Chemo A091305 N  
    Y ALLIANCE A091404 HN, AR+, Enzalutamide A091404 N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
PILOT LUNG Y SWOG S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC S1619 N  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N  
  ERLYTX Y ALLIANCE A071102 GBM, adj TMZ +/- Veliparib A071102 N  
    Y COG ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) ARST1321 N  
  GI Y ALLIANCE N1048 Rectal,LocalAdv,ChemoRT+/-FOLFOX N1048 Y  
  GU Y NRG NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG-GU002 N  
  LEUK Y SWOG S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics S1612 N  
  LUNG Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
  MELAN Y ECOG-ACRIN EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG G0286B Adv Endometrial,Metformin/Chemo GOG-0286B Y  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
    Y NRG G0281 Ovar, Recur/prog LG, IC chemo vs trametinib GOG-0281 Y  
III BREAST N   S1222 Brst,Fulv. +/- Ever. +/- Anastr.   N Y
    Y SWOG S1207 Brst,Adj,Endocrine+/-Everolimus S1207 Y  
    Y SWOG S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) S1418 Y  
    Y ALLIANCE A011202 Breast, Nodal XRT +/- ALND A011202    
    Y ALLIANCE A011106 Breast, Neoadj, ALTERNATE study A011106 N  
    Y NRG B51 Breast, Regional Nodal XRT NSABP-B-51 Y  
    Y ALLIANCE A011401 Breast, adj, Stage II/III HER2-, weight loss A011401 Y  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y ECOG-ACR E2112 Brst,Adv,Exemestane+/-Entinostat E2112 Y  
    Y ALLIANCE A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo A011502 Y  
    Y ECOG-ACRIN EA1151 Brst, Tomosynthesis Mammographic Screening EA1151 N  
    Y NRG B55 Brst, Adj Olaparib for BRCA,TNBC NSABP-B-55 Y  
  CCD Y SWOG S1415CD TrACER CSF Standing Order Intervention for FN S1415CD Y  
    Y ALLIANCE A011104 Preoperative Breast MRI A011104 Y  
    Y Alliance A191402C PROS, Testing Decision Aids for Minority Men A191402CD Y  
  GI Y NRG R0848 Panc, Adj, Erlotinib v ChemoRT RTOG-0848 Y  
    Y ALLIANCE A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC A021502 Y  
    Y NRG NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG-GI004 N  
  GU Y SWOG S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG S1602 Y  
    Y NRG R0924 Pros, NADT+WPRT vs. NADT+P&SV RT RTOG-0924 Y  
    Y ECOG-ACR EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) EA8143 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
  LEUK Y ECOG-ACRIN E2906 AML, Age 60+, Clo vs Dauno+Cy E2906 Y  
    Y ECOG-ACRIN E1910 BCR-ABL-neg, B ALL, Blinatumomab E1910 N  
  LUNG Y ALLIANCE C30610 SCLC, Thoracic RT CALGB-30610 Y  
    Y ALLIANCE A081105 ALCHEMIST1, EGFR mut, Erlotinib A081105 N  
    Y ECOG-ACRIN EA5142 ALCHEMIST3, Non-match, Nivolumab EA5142 N  
    Y ECOG-ACR E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
  LYMPH Y ECOG-ACRIN EA4151 Lymph, AHCT +/-Ritux, MRD Neg EA4151 Y  
    Y ALLIANCE A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo A051301 N  
  MELAN Y ECOG-ACR EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T EA6134 Y  
  MMYEL Y ECOG-ACRIN E1A11 MM, frontline, BLD vs CLD E1A11 Y  
  OTHER Y NRG R0920 HN, Adv, Postop IMRT ± Cetuximab RTOG-0920 Y  
    Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT GOG-0263 Y  
    Y NRG NRGGY011 ENDO, SURG WINDOW, MPA VS MPA+ENTINOSTAT NRG-GY011 N  
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
  SURV Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y ECOG-ACR E1Q11 EROS: Reproductive Health in Cancer Survivors E1Q11 Y  
  SXQOL Y ALLIANCE A221101 Glioma, Nuvigil/Placebo Fatigue A221101 Y  
    Y NRG NRGGU003 Pros, Post-Prostatectomy HYPORT vs COPORT NRG-GU003 Y